



- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *A61P 11/06* (2006.01)
- (21) **International Application Number:**
PCT/US2024/029836
- (22) **International Filing Date:**
17 May 2024 (17.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/503,089 18 May 2023 (18.05.2023) US
63/597,219 08 November 2023 (08.11.2023) US
63/547,945 09 November 2023 (09.11.2023) US
- (71) **Applicant:** **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US).
- (72) **Inventors:** **AMBROSE, Christopher, Seabrook**; One MedImmune Way, Gaithersburg, MD 20878 (US). **MARTIN, Neil**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave, Cambridge CB2 0AA (GB). **COOK, William**; One MedImmune Way, Gaithersburg, MD 20878 (US). **PONNARAMBIL, Sandhya**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave, Cambridge CB2 0AA (GB).
- (74) **Agent:** **NEVILLE, Katherine, L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** TREATMENT OF CORTICOSTEROID DEPENDENT ASTHMA WITH ANTI-TSLP ANTIBODY

Figure 1



(57) **Abstract:** The present disclosure relates, in general, to methods of treating corticosteroid-dependent asthma, such as oral corticosteroid (OCS)-dependent asthma using an antibody specific for thymic stromal lymphopoietin (TSLP).